Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome

This study has been completed.
H. Lundbeck A/S
Information provided by (Responsible Party):
Jae-Min Kim, Chonnam National University Hospital Identifier:
First received: January 5, 2007
Last updated: June 11, 2013
Last verified: June 2013
This study aimed to evaluate the efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome (CAS).

Condition Intervention Phase
Depressive Disorder
Coronary Disease
Drug: Escitalopram
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial

Resource links provided by NLM:

Further study details as provided by Chonnam National University Hospital:

Primary Outcome Measures:
  • Score on the Hamilton Depression Rating Scale-17 item [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Scores on the Beck Depression Inventory [ Time Frame: 24 weeks ]
  • Changes in electrocardiographic, echocardiographic, and angiographic variables [ Time Frame: 24 weeks ]
  • Scores on the Montgomery Asberg Depression Rating Scale [ Time Frame: 24 weeks ]
  • Scores on the Clinical Global Impression scale [ Time Frame: 24 weeks ]
  • Scores on the World Health Organization Quality of Life scale [ Time Frame: 24 weeks ]
  • Scores on the Social and Occupational Functioning Assessment Scale [ Time Frame: 24 weeks ]
  • Scores on the World Health Organization Disability Assessment Schedule [ Time Frame: 24 weeks ]

Enrollment: 300
Study Start Date: May 2007
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Escitalopram Drug: Escitalopram
Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
Other Names:
  • Lexapro
  • Cipralex
Placebo Comparator: Placebo pill Drug: Placebo
Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.

Detailed Description:
Depression is common in patients with acute CAS and increases cardiac morbidity and mortality. However, there are a few limited data available regarding the effects and safety of antidepressants for treating depression in patients with acute CAS. This study aims to investigate whether escitalopram might be an effective treatment option for these patients.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18~85
  • Diagnosed as acute CAS (unstable angina or acute myocardial infarction) and being conducted coronary angiography
  • Beck Depression Inventory > 10 and major or minor depressive disorder by the DSM-IV criteria
  • With ability to complete various questionnaires
  • Can understand the objective of the study and sign informed consent

Exclusion Criteria:

  • Occurrence of acute CAS while the patient was hospitalized for another reason, except for CAS
  • Current CAS developed less than 3 months after coronary artery bypass graft procedure
  • Uncontrolled hypertension (systolic BP > 180mmHg or diastolic BP > 100mmHg)
  • Resting heart rate < 40/min
  • Severe physical illnesses threatening life or interfering with the recovery from CAS
  • Persistent clinically significant laboratory abnormalities
  • Concomitant use of class I antiarrhythmic medications; reserpine, guanethidine, clonidine, or methyldopa; anticonvulsants or neuroleptics
  • History of neuropsychiatric illnesses such as dementia, Parkinson's disease, brain tumor, psychoses, alcoholism, and other substance dependence
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00419471

Korea, Republic of
Chonnam National University Hospital
Gwangju, Korea, Republic of, 501-757
Sponsors and Collaborators
Chonnam National University Hospital
H. Lundbeck A/S
Principal Investigator: Jin-Sang Yoon, MD & PhD Chonnam National University Hospital
Study Director: Jae-Min Kim, MD & PhD Chonnam National University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jae-Min Kim, Associate Professor, Chonnam National University Hospital Identifier: NCT00419471     History of Changes
Other Study ID Numbers: LIIS-11592A
Study First Received: January 5, 2007
Last Updated: June 11, 2013

Keywords provided by Chonnam National University Hospital:
Myocardial infarction
Angina, unstable

Additional relevant MeSH terms:
Depressive Disorder
Coronary Disease
Coronary Artery Disease
Mood Disorders
Mental Disorders
Behavioral Symptoms
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents processed this record on April 21, 2017